8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 12, 2026·SEC
Material company update
Dec 18, 2025·SEC
Syra Health Corp. Class A Common Stock(SYRA)Earnings, Financials & Key Ratios
SYRA•NASDAQ
$0.54
Price updated Jul 6, 2026
AboutSyra Health Corp., a healthcare services company, provides health education, population health management, behavioral and mental health, healthcare workforce, and digital health services in the United States. It offers health education services, including medical communications, patient education, and healthcare training; and population health management services, such as analytics as a service, epidemiology, and health equity analytics solutions. The company also engages in developing Syrenity, an on-demand telehealth platform for mental health services. In addition, the company provides healthcare staffing solutions; and digital health solutions comprising digital transformation, cloud and security, artificial intelligence, patient engagement, and health apps. It serves mental health hospitals and organizations, including government agencies, integrated health networks, managed care entities, and pharmaceutical manufacturers. Syra Health Corp. was incorporated in 2020 and is headquartered in Carmel, Indiana.Show more
- Revenue$7M-9.5%
- EBITDA-$884K+76.1%
- Net Income-$896K+76.2%
- EPS (Diluted)-0.08+85.5%
- Gross Margin34.43%+66.3%
- EBITDA Margin-12.23%+73.6%
- Operating Margin-12.51%+73.5%
- Net Margin-12.4%+73.7%
- ROE-36.02%+67.0%
SYRA Price & Volume
Syra Health Corp. Class A Common Stock (SYRA) stock price & volume — 10-year historical chart
Loading chart...
Volatile Revenue Growth Masks Persistent Operational Losses
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Capital exhaustion and dilution
Key Thesis Takeaways
- Syra Health Corp.
- faces significant structural challenges as its reliance on lumpy, project-based government contracts drives inconsistent revenue performance, evidenced by a 22.4% growth rate in 2026Q1 following multiple quarters of contraction.
- The company's inability to achieve consistent operating leverage, with SG&A expenses frequently outpacing gross profit, suggests a high risk of continued shareholder dilution.
- Investors should remain cautious given the $9.5M accumulated deficit and the precarious nature of the firm's $2.9M cash position relative to its history of negative net margins.
Verdict Logic
the company's inability to maintain consistent profitability, underscored by a net margin that reached -82.6% in 2024Q1, suggests that the current business model lacks the necessary scale to avoid future dilutive financing.
SYRA Growth Metrics
Syra Health Corp. Class A Common Stock (SYRA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years8.75%
TTM-5.51%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM93.42%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM95.84%
Return on Capital
10 Years-151.47%
5 Years-151.47%
3 Years-87.35%
Last Year-35.02%
Peers Comparison
Key metrics vs top competitors for Syra Health Corp. Class A Common Stock (SYRA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.54 | $6.14M | -7.16 | -9.47% | -12.4% | -36.02% | — | |
| $5.20 | $871.07M | 130.00 | 22% | 0.49% | 1.03% | — | |
| $98.52 | $6.52B | 71.91 | 15.24% | 9.48% | 5.13% | — | |
| $5.06 | $2.62B | -29.76 | 40.34% | -2.58% | -17.08% | — | |
| $4.91 | $237.46M | -21.35 | -8.66% | -7.76% | -162.38% | — | |
| $6.35 | $119.16M | 23.52 | 18.78% | 6.37% | 5.47% | — |
Compare SYRA vs Peers
Syra Health Corp. Class A Common Stock (SYRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SYRA SEC Filings & Documents
Syra Health Corp. Class A Common Stock (SYRA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when SYRA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SYRA Frequently Asked Questions
Syra Health Corp. Class A Common Stock (SYRA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Syra Health Corp. Class A Common Stock's revenue?
Syra Health Corp. Class A Common Stock (SYRA) reported $7.6M in revenue for fiscal year 2025.
How fast is Syra Health Corp. Class A Common Stock growing?
Syra Health Corp. Class A Common Stock (SYRA) saw revenue decline by 9.5% over the past year.
Is SYRA profitable?
Syra Health Corp. Class A Common Stock (SYRA) reported a net loss of $0.2M for fiscal year 2025.
Dividend & Returns
What is SYRA's return on equity?
Syra Health Corp. Class A Common Stock (SYRA) has a return on equity (ROE) of -36.0%. Negative ROE indicates the company is unprofitable.
What is Syra Health Corp. Class A Common Stock's free cash flow?
Syra Health Corp. Class A Common Stock (SYRA) generated $0.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.